Zealand Pharma ASZLDPF 62 PB Ratio is 1.35 as of Jun. 27, 2026, which is 79% below its 10-year median of 6.36. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,920.24 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Zealand Pharma AS ranks better than 72.65% on this metric.
The historical rank and industry rank for Zealand Pharma AS's PB Ratio or its related term are showing as below:
ZLDPF'
s PB Ratio Range Over the Past 10 Years
Min: 1.12 Med: 6.36 Max: 28.87
Current: 1.4
During the past 13 years, Zealand Pharma AS's highest PB Ratio was 28.87. The lowest was 1.12. And the median was 6.36.
ZLDPF's PB Ratio is ranked better than 72.65% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ZLDPF: 1.40
During the past 12 months, Zealand Pharma AS's average Book Value Per Share Growth Rate was 74.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 136.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 55.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 24.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zealand Pharma AS was 136.60% per year. The lowest was -21.80% per year. And the median was 16.70% per year.
Back to Basics: PB Ratio
Zealand Pharma AS (OTCPK:ZLDPF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zealand Pharma AS PB Ratio Related Terms
Zealand Pharma AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zealand Pharma AS (ZLDPF) has a PB Ratio of 1.35 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zealand Pharma AS and its competitors. This is 79% below median its historical median of 6.36. Over the past decade, Zealand Pharma AS's PB Ratio has ranged from 1.12 to 28.87. According to the industry distribution chart, Zealand Pharma AS ranks #337 out of 1232 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Zealand Pharma AS's PB Ratio too high?
Zealand Pharma AS's current PB Ratio of 1.35 is 79% below median its 10-year median of 6.36. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 28.87. The Biotechnology industry median PB Ratio is 2.80. Zealand Pharma AS's value of 1.35 is 51.8% below this industry median. Based on the distribution chart, Zealand Pharma AS ranks #337 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #337 out of 1232 companies for PB Ratio. This puts Zealand Pharma AS in the upper half of its industry. The industry median PB Ratio is 2.80. Zealand Pharma AS's value of 1.35 is 51.8% below this benchmark. Historically, Zealand Pharma AS's own PB Ratio has ranged from 1.12 to 28.87 over the past decade. While the company's 10-year median is 6.36 vs. the industry median of 2.80, Zealand Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current PB Ratio of 1.35 is 51.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current PB Ratio is 1.35, which is 79% below median its own 10-year median of 6.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,920.24, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current PB Ratio is 1.35, which is 79% below median its 10-year median of 6.36 and 51.8% below the Biotechnology industry median of 2.80. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current PB Ratio is 1.35 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,920.24.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
PB Ratio: 1.35 (79% below median its 10-year median of 6.36)
GF Value™: $1,920.24 vs. price of $42.89 (97.8% below fair value)
Industry Position: 51.8% below the Biotechnology median (#337 of 1232)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
